JP2019528046A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2019528046A5 JP2019528046A5 JP2019501641A JP2019501641A JP2019528046A5 JP 2019528046 A5 JP2019528046 A5 JP 2019528046A5 JP 2019501641 A JP2019501641 A JP 2019501641A JP 2019501641 A JP2019501641 A JP 2019501641A JP 2019528046 A5 JP2019528046 A5 JP 2019528046A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- antigen
- binding fragment
- amino acid
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 claims description 152
- 102000036639 antigens Human genes 0.000 claims description 152
- 108091007433 antigens Proteins 0.000 claims description 152
- 239000012634 fragment Substances 0.000 claims description 152
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 100
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims description 48
- 108010027445 interleukin-22 receptor Proteins 0.000 claims description 42
- 102000009548 interleukin-22 receptor activity proteins Human genes 0.000 claims description 42
- 230000004913 activation Effects 0.000 claims description 16
- 230000001419 dependent effect Effects 0.000 claims description 16
- 102000040430 polynucleotide Human genes 0.000 claims description 16
- 108091033319 polynucleotide Proteins 0.000 claims description 16
- 239000002157 polynucleotide Substances 0.000 claims description 16
- 238000006467 substitution reaction Methods 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 6
- 239000013604 expression vector Substances 0.000 claims description 4
- 206010012438 Dermatitis atopic Diseases 0.000 claims description 3
- 201000004681 Psoriasis Diseases 0.000 claims description 3
- 201000001263 Psoriatic Arthritis Diseases 0.000 claims description 3
- 208000036824 Psoriatic arthropathy Diseases 0.000 claims description 3
- 201000008937 atopic dermatitis Diseases 0.000 claims description 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical group C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims description 2
- 235000002198 Annona diversifolia Nutrition 0.000 claims description 2
- 241000282842 Lama glama Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 238000012258 culturing Methods 0.000 claims description 2
- 239000003814 drug Substances 0.000 claims description 2
- 238000004519 manufacturing process Methods 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- 108090000623 proteins and genes Proteins 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 claims description 2
- 230000001105 regulatory effect Effects 0.000 claims description 2
- 241000282832 Camelidae Species 0.000 claims 1
- 239000000126 substance Substances 0.000 description 20
- 238000012986 modification Methods 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1612337.4 | 2016-07-15 | ||
| GBGB1612337.4A GB201612337D0 (en) | 2016-07-15 | 2016-07-15 | Ant-il-22r antibodies |
| PCT/EP2017/067923 WO2018011420A1 (en) | 2016-07-15 | 2017-07-14 | Anti-il-22r antibodies |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2019528046A JP2019528046A (ja) | 2019-10-10 |
| JP2019528046A5 true JP2019528046A5 (enExample) | 2020-08-06 |
| JP7163275B2 JP7163275B2 (ja) | 2022-10-31 |
Family
ID=56890507
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019501641A Active JP7163275B2 (ja) | 2016-07-15 | 2017-07-14 | 抗－ｉｌ－２２ｒ抗体 |
Country Status (27)
| Country | Link |
|---|---|
| US (4) | US10696741B2 (enExample) |
| EP (2) | EP4023674A3 (enExample) |
| JP (1) | JP7163275B2 (enExample) |
| KR (2) | KR20230128137A (enExample) |
| CN (1) | CN109641966B (enExample) |
| AU (1) | AU2017296094B2 (enExample) |
| BR (1) | BR112019000788A2 (enExample) |
| CA (1) | CA3024370A1 (enExample) |
| CY (1) | CY1125041T1 (enExample) |
| DK (1) | DK3484921T3 (enExample) |
| ES (1) | ES2903412T3 (enExample) |
| GB (1) | GB201612337D0 (enExample) |
| HR (1) | HRP20220197T1 (enExample) |
| HU (1) | HUE057615T2 (enExample) |
| IL (1) | IL264262B2 (enExample) |
| LT (1) | LT3484921T (enExample) |
| MX (1) | MX2019000539A (enExample) |
| MY (1) | MY197821A (enExample) |
| PL (1) | PL3484921T3 (enExample) |
| PT (1) | PT3484921T (enExample) |
| RS (1) | RS62884B1 (enExample) |
| RU (1) | RU2758721C2 (enExample) |
| SA (1) | SA519400856B1 (enExample) |
| SG (1) | SG11201900128XA (enExample) |
| SI (1) | SI3484921T1 (enExample) |
| UA (1) | UA125585C2 (enExample) |
| WO (1) | WO2018011420A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
| WO2019236585A1 (en) * | 2018-06-05 | 2019-12-12 | Bioatla, Llc | Anti-il-22 antibodies, antibody fragments, their immunoconjugates and uses thereof |
| CN110302363B (zh) * | 2019-07-04 | 2020-10-09 | 北京大学第三医院（北京大学第三临床医学院） | Il-22作为制备治疗pcos药物的应用及药物制剂 |
| WO2023232789A1 (en) | 2022-06-03 | 2023-12-07 | Leo Pharma A/S | Liquid formulation of il-22r antibody |
| WO2024184333A1 (en) | 2023-03-08 | 2024-09-12 | Leo Pharma A/S | Il-22r antibody for use in treating atopic dermatitis |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5892019A (en) | 1987-07-15 | 1999-04-06 | The United States Of America, As Represented By The Department Of Health And Human Services | Production of a single-gene-encoded immunoglobulin |
| MXPA05010134A (es) * | 2003-03-24 | 2005-11-16 | Zymogenetics Inc | Anticuerpos anti-il-20, metodos y moleculas de enlace que se usan en la inflamacion. |
| US7537761B2 (en) | 2004-10-22 | 2009-05-26 | Zymogenetics, Inc. | Anti-IL-22RA antibodies and binding partners and methods of using in inflammation |
| EP1954719A2 (en) * | 2005-12-02 | 2008-08-13 | Genentech Inc. | Compositions and methods for the treatment of diseases and disorders associated with cytokine signaling involving antibodies that bind to il-22 and il-22r |
| GB2461546B (en) | 2008-07-02 | 2010-07-07 | Argen X Bv | Antigen binding polypeptides |
| PH12012500924A1 (en) * | 2009-11-19 | 2012-11-26 | Merck Serono Sa | Humanized antibodies against human il-22ra |
| GB2476681B (en) | 2010-01-04 | 2012-04-04 | Argen X Bv | Humanized camelid VH, VK and VL immunoglobulin domains |
| GB2504139B (en) * | 2012-07-20 | 2014-12-31 | Argen X Bv | Antibodies to highly conserved targets produced by the immunisation of Camelidae species |
| WO2013087911A1 (en) * | 2011-12-16 | 2013-06-20 | Synthon Biopharmaceuticals B.V. | Compounds and methods for treating inflammatory diseases |
| JP6391574B2 (ja) | 2012-08-31 | 2018-09-26 | アルゲン−エックス ビーブイビーエー | 種間標的内交差反応性を有する抗体分子を産生する方法 |
| US10093737B2 (en) * | 2013-03-01 | 2018-10-09 | Albert Einstein College Of Medicine, Inc. | HHLA2 as a novel inhibitor of human immune system and uses thereof |
| CN105601739B (zh) * | 2016-02-22 | 2019-01-18 | 王晨辉 | 一种人源化抗白介素22基因工程抗体及其应用 |
| GB201612337D0 (en) | 2016-07-15 | 2016-08-31 | Argen-X N V | Ant-il-22r antibodies |
-
2016
- 2016-07-15 GB GBGB1612337.4A patent/GB201612337D0/en not_active Ceased
-
2017
- 2017-07-14 IL IL264262A patent/IL264262B2/en unknown
- 2017-07-14 SG SG11201900128XA patent/SG11201900128XA/en unknown
- 2017-07-14 MY MYPI2018002752A patent/MY197821A/en unknown
- 2017-07-14 HU HUE17746011A patent/HUE057615T2/hu unknown
- 2017-07-14 EP EP21208038.6A patent/EP4023674A3/en not_active Withdrawn
- 2017-07-14 LT LTEPPCT/EP2017/067923T patent/LT3484921T/lt unknown
- 2017-07-14 ES ES17746011T patent/ES2903412T3/es active Active
- 2017-07-14 CN CN201780053328.1A patent/CN109641966B/zh active Active
- 2017-07-14 KR KR1020237028376A patent/KR20230128137A/ko not_active Ceased
- 2017-07-14 EP EP17746011.0A patent/EP3484921B1/en active Active
- 2017-07-14 DK DK17746011.0T patent/DK3484921T3/da active
- 2017-07-14 MX MX2019000539A patent/MX2019000539A/es unknown
- 2017-07-14 AU AU2017296094A patent/AU2017296094B2/en active Active
- 2017-07-14 PT PT177460110T patent/PT3484921T/pt unknown
- 2017-07-14 UA UAA201901458A patent/UA125585C2/uk unknown
- 2017-07-14 SI SI201731037T patent/SI3484921T1/sl unknown
- 2017-07-14 BR BR112019000788A patent/BR112019000788A2/pt unknown
- 2017-07-14 CA CA3024370A patent/CA3024370A1/en active Pending
- 2017-07-14 RU RU2019103991A patent/RU2758721C2/ru active
- 2017-07-14 PL PL17746011T patent/PL3484921T3/pl unknown
- 2017-07-14 KR KR1020197001500A patent/KR102571012B1/ko active Active
- 2017-07-14 RS RS20220105A patent/RS62884B1/sr unknown
- 2017-07-14 WO PCT/EP2017/067923 patent/WO2018011420A1/en not_active Ceased
- 2017-07-14 HR HRP20220197TT patent/HRP20220197T1/hr unknown
- 2017-07-14 JP JP2019501641A patent/JP7163275B2/ja active Active
-
2019
- 2019-01-08 US US16/242,760 patent/US10696741B2/en active Active
- 2019-01-10 SA SA519400856A patent/SA519400856B1/ar unknown
- 2019-10-23 US US16/661,757 patent/US11261246B2/en active Active
- 2019-10-23 US US16/661,783 patent/US11447544B2/en active Active
-
2022
- 2022-02-04 CY CY20221100099T patent/CY1125041T1/el unknown
- 2022-08-11 US US17/819,161 patent/US20230088269A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018183173A5 (enExample) | ||
| JP2020528768A5 (enExample) | ||
| CN115003333A (zh) | Pvrig结合蛋白及其医药用途 | |
| JP2018035138A5 (enExample) | ||
| JP2019528046A5 (enExample) | ||
| RU2014122990A (ru) | Способы комбинированной терапии с применением молекул, связывающихся с psl и pcrv pseudomonas | |
| JP2014509861A5 (enExample) | ||
| RU2016100892A (ru) | Антитела против tweakr и их применение | |
| CN109843927A (zh) | 抗b7-h3抗体、其抗原结合片段及其医药用途 | |
| RU2018100820A (ru) | ГУМАНИЗИРОВАННЫЕ АНТИТЕЛА И АНТИТЕЛА С СОЗРЕВШЕЙ АФФИННОСТЬЮ ПРОТИВ FcRH5 И СПОСОБЫ ИХ ПРИМЕНЕНИЯ | |
| JP2011509245A5 (enExample) | ||
| RU2012112829A (ru) | Анти-gitr-антитела | |
| JP2015503909A5 (enExample) | ||
| RU2010107175A (ru) | Антитела человека к cd20 человека и способ их использования | |
| JP2017532037A5 (enExample) | ||
| JP2012525829A5 (enExample) | ||
| RU2018131123A (ru) | Антитела к tgf-бета2 | |
| HRP20200767T1 (hr) | Humanizirana anti-humana cd19 protutijela i postupci uporabe | |
| JP2018510617A5 (enExample) | ||
| NZ758448A (en) | Anti-sortilin antibodies and methods of use thereof | |
| JP2015504421A5 (enExample) | ||
| JP2019511911A5 (enExample) | ||
| JP2014519334A5 (enExample) | ||
| JP2012532851A5 (enExample) | ||
| RU2013110874A (ru) | Антитела против il-18r1 и их применения |